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P-glycoprotein (Pgp, ABCB1), multidrug resistance associated protein 1 (MRP1, 
ABCC1) and breast cancer resistance protein (BCRP, ABCG2) are active efflux pumps 
that are able to extrude a large variety of lipophilic chemotherapeutic drugs from the 
cells, causing the phenomenon of multidrug resistance. The intimate association of the 
transporters with the plasma membrane implies that it may have strong modulatory 
effects on their catalytic function.  
Rafts are isolated from bulk cellular membrane by density gradient centrifugation in the 
presence of the non-ionic detergents e.g. Triton X-100 (TX-100) or Brij 98. It has been proposed 
that lipid rafts are composed of a highly ordered, TX-100-insoluable core region, rich in 
sphingolipids and cholesterol, which is surrounded by a less structured shell (resistant to milder 
detergents, e.g. Brij 98) and then pass into a bulk liquid disordered membrane phase. Pgp and 
ABCG2 molecules reside in partially different membrane territories. Most of the cell 
surface ABCG2 molecules (>80 %) reside in the Brij 98 and TX-100 resistant core region 
of the rafts. However, only 10-40 % of Pgp molecules are found in the TX-100 resistant 
rafts and/or caveolae in various cell lines including NIH 3T3 MDR1, A431 and MDCK 
cells, while the rest of Pgps are localized in the TX-100 soluble, but Brij 98 resistant shell 
region of rafts (Goda et al. 2009, Current Cancer Drug Target). 
 
Topological heterogeneity of cell surface Pgps determines their functional state 
P-glycoprotein (Pgp), is present in two subpopulations in the plasma membrane of 
many cell types, distinguished by a conformation sensitive antibody: Pool I is recognized 
by the UIC2 mAb even in the absence of substrates/modulators, while pool II Pgps bind 
this mAb only in their presence. However, when we permeabilize the cells by 
Staphylococcus aureus alpha toxin and wash out their ATP content, or deplete the ATP 
of intact cells by Na-azide and deoxy-glucose, all the cell surface Pgps become UIC2 
mAb reactive. At the same time the catalytically inactive double Walker A mutant Pgps 
are recognized by the UIC2 mAb in the absence of substrates/modulators and without 
ATP depletion. These data suggest that pool I Pgps are in an ATP-free state. In addition, 
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we measured strong co-localization between the Pgp substrate vinblastine-BPY and 
UIC2-bound pool I Pgps in the membrane, suggesting that the pool I Pgps are in a drug 
binding state. The raft associated Pgps have about 7 fold lower affinities to ATP 
compared to the non-raft Pgps. The two Pgp pools can also be distinguished in terms of 
their membrane microdomain localization and intracellular molecular neighbours, since 
pool I Pgps are highly associated with the TX-100 resistant rafts and the cytoskeleton. 
Endocytosis of Pgps proceeds mainly from the dominantly raft associated pool I and 
involves caveolae and the actin microfilament system. Depletion of ATP switches pool II 
Pgps from the UIC2 non-reactive conformation to the UIC2 reactive conformation, but it 
does not affect their raft and cytoskeleton association. While restitution of normal 
intracellular ATP level switches pool II Pgps back to the UIC2 non-reactive state. Thus 
we propose that the raft associated pool I Pgps have too high KM for ATP to become 
saturated at physiological ATP concentrations and they preferentially engaged in 
trafficking processes, while pool II Pgps are saturated with ATP and involved in substrate 
transport. (The manuscript will be submitted soon.) 
 
Molecular interaction partners of the transporters 
 We aimed to identify interaction partners of the examined transporters in co-
immunoprecipitation experiments. The co-precipitated proteins were separated by SDS 
PAGE and the excised protein bands were analysed by MALDI.  When we used whole 
cell lysates to immunoprecipitate Pgp the majority of the co-precipitated proteins were 
cytoskeleton associated and probably involved in the caveolae-mediated endocytosis of 
Pgp in addition to some membrane proteins (e.g. ERGIC 53, stim1, Aspartyl/asparaginyl 
beta-hydroxylase, delta-1-pyrroline-5-carboxylate synthetase, synaptotagmin-1) and a 
heat sock protein (hsp71). 
In further experiments Pgp and ABCG2 proteins were immunoprecipitated in 
RIPA buffer from a plasma-membrane rich fraction of cells. In these experiments hsp71 
and myosin-9 were co-immunoprecipitated with both Pgp and ABCG2. Since these 
proteins may potentially affect the expression or function of the examined transporters we 
examine this issue by silencing hsp71 and myosin-9. 
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Interactions of retinoids with P-glycoprotein, ABCG2 and MRP1 
We examined the effect of several retinoids (e.g. retinol, all-trans-retinoic acid, 
all-trans-4-oxo-retinoic acid, 9-cis-retinoic acid, 9-cis-4-oxo-retinoic acid, 13-cis-retinoic 
acid and 13-cis-4-oxo retinoic acid and retinyl-acetate) on the transport and ATPase 
activity of Pgp, ABCG2 and MRP1. For the measurement of ATPase activity we used 
isolated cell membranes derived from MDCK (dog kidney epithelia) and Sf9 (Spodoptera 
frugiperda) cells expressing human Pgp, ABCG2 or MRP1 at high levels. We found that 
only 9-cis-4-oxo-retinoic acid has a weak stimulatory effect on the basal ATPase activity 
of ABCG2 at high concentrations. Retinol, 13-cis-retinoic acid, 13-cis-4-oxo-retinoic 
acid and retinyl-acetate inhibit the basal- and substrate-stimulated ATPase activity of 
Pgp, ABCG2 and MRP1 in a micromolar concentration range. Interestingly, 13-cis-
retinoic acid inhibits the transporters, while 9-cis-retinoic acid and all-trans-retinoic acid 
do not have any effect, besides that they are stereo-isomers, suggesting that stereo-
chemical differences also affect the interactions between the retinoids and the 
transporters.  
 Since the physiological tissue and blood concentration of the different retinoids is 
in the nanomolar range (1-20 nM), it is unlikely that they interfere with the transport 
activity of the examined ABC transporters. However, retinoid therapy or retinol 
supplementation may cause high enough local retinol concentrations in the intestinal 
lumen that inhibits Pgp and ABCG2 expressed in the intestinal epithelium and 
consequently may result in intestinal absorption of their toxic substrates. 
(We have prepared a manuscript from the above results and submit it to the Eur. J 
Pharmacology) 
 
Elucidation of the catalytic mechanism of P-glycoprotein (Pgp): 
 According to three-dimensional models based on crystal structures of ABC 
proteins the TMDs are always in outward facing conformation in the nucleotide-bound 
form of the protein, as opposed to the inward facing nucleotide-free form, where the 
bundle of trans-membrane helices is closed on the extracellular side. Despite 
accumulating structural and functional data, it is still unknown how ATP binding and 
hydrolysis are connected to the conformational changes that allow trans-membrane 
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transport. The discontinuous extracellular epitope of the UIC2 mAb is sensitive to the 
switch between the above conformational states, as reflected by antibody binding. It was 
previously shown by Druley et al. (2001) that nucleotide binding to the ABC domains 
decreases the UIC2 reactivity of Pgp in a concentration dependent manner in cells 
permeabilized by Staphylococcus aureus alpha toxin. Following the same strategy, we 
have studied how substrates, hydrolysable and non-hydrolysable nucleotides and 
phosphate analogues affect the formation of the above catalytic intermediates 
discriminated on the basis of UIC2 reactivity. To elucidate partial catalytic reactions, we 
studied Pgp variants carrying mutations in the conserved Walker A region (K433M and 
K1076M) of either the N-terminal or C-terminal ABC domains or both. Although 
mutation of these key residues have been shown to abolish ATPase and transport activity, 
we found that single mutants possessed a residual drug efflux activity (the double mutant 
variant was indeed inactive).  
 We have found that nucleotide binding itself is sufficient to switch Pgp from the 
inward facing (UIC2 binding) to the outward facing (UIC2-nonbinding) TMD 
conformation in both wild-type and single Walker A mutant Pgp variants. Similarly to 
wild-type Pgp, single Walker A mutants can also be trapped in the post-hydrolysis state 
in the presence of ATP and vanadate (Vi) or BeFx, suggesting that these variants are 
capable of ATP hydrolysis. Formation of the BeFx-trapped complex is facilitated by 
substrates both in the wild-type and the single Walker A mutant Pgp variants. 
Interestingly, cells expressing single or double Walker A mutant Pgp variants accumulate 
the Pgp substrate vinblastine-bodipy in their plasma membranes. Based on confocal 
microscopic images vinblastine-bodipy staining strongly co-localized with Pgp molecules 
and could be prevented by CsA or Vi treatment. The above data support a model in which 
Pgp molecules seesaw between the nucleotide-free inward facing conformation 
characterized by high drug affinity and the nucleotide-bound outward facing 
conformation(s) with low drug affinity. Binding of ATP is sufficient to switch Pgps from 
the inward facing to the outward facing conformation. Pgps trapped in the post-
hydrolysis state by phosphate analogues e.g. Vi are still in the low drug affinity 
conformation, while release of nucleotides resets them to the high drug affinity 
conformation.  
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 (Based on these data we presented posters and lectures and now we are preparing a 
manuscript). 
 
Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic 
radiotracers, 99mTc-MIBI and 18FDG  
 Using the UIC2 monoclonal antibody we made some interesting observations 
which were not included in the project plans. These data may promote the in vivo 
application of the UIC2 mAb for reversal of Pgp-mediated drug resistance after 
humanization of the antibody.  
The UIC2 monoclonal antibody recognizes human Pgp and inhibits its drug 
transport activity. However, this inhibition is partial, since the majority of Pgps are not 
accessible to this antibody and they become UIC2 reactive only in the presence of certain 
substrates or modulators (e.g. cyclosporine A (CsA)). We have shown earlier that the 
combined application of a class of Pgp modulators (e.g. cyclosporine A and SDZ PSC 
833) used at low concentrations and UIC2 antibody specifically and effectively blocks 
the transport activity of Pgp in vitro (Goda et al. 2007). In this project we studied the 
UIC2 antibody mediated Pgp inhibition in more detail measuring the accumulation of 
tumor diagnostic radiotracers, 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) and 
[99mTc]hexakis-2-methoxybutyl isonitrile (99mTc-MIBI), into Pgp+ (A2780AD) and Pgp- 
(A2780) human ovarian carcinoma cells. 
 Co-incubation of cells with UIC2 and cyclosporine A (CSA, 2 µM) increased the 
binding of UIC2 more than 3 fold and reverted the rhodamine 123 (R123), daunorubicin 
(DNR) and 99mTc-MIBI accumulation of the Pgp+ 2780AD cells to approx. the same level 
as observed in Pgp- cells. Similarly, 50 µM paclitaxel (Pacl) increased UIC2 binding, and 
consequently reinstated the uptake of R123, DNR and 99mTc-MIBI into the Pgp+ cells. 
Blocking Pgp by combined treatments with CSA+UIC2 or Pacl + UIC2 also decreased 
the glucose metabolic rate of the A2780AD Pgp+ cells measured in 18FDG accumulation 
experiments suggesting that the maintenance of Pgp activity requires a considerable 
amount of energy. Similar treatments of the A2780 Pgp- cells did not result in significant 
change in the R123, DNR, 99mTc-MIBI and 18FDG accumulation demonstrating that the 
above effects are Pgp-specific. Thus, combined treatment with the UIC2 antibody and 
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Pgp modulators can completely block the function of Pgp in human ovarian carcinoma 
cells and this effect can be followed in vitro by using tumor-diagnostic radiotracers, 
99mTc-MIBI and 18FDG. (Krasznai ZT et al. 2010 Eur J Pharm). 
 
The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the 
combined result of Pgp inhibition and antibody dependent cell-mediated 
cytotoxicity  
We also tested whether the combined treatment with CsA and UIC2 mAb can 
potentiate the anti-tumor effect of doxorubicin (DOX) in Pgp+ tumors to achieve 
clinically relevant reduction in tumor size, applying SCID mice xenotransplanted with 
Pgp+ and Pgp- tumors. Tumor growth was followed by weighing the mass of the tumors 
in sacrificed animals and also in vivo on the basis of 18FDG accumulation. In the latter 
case a small-animal Positron Emission Tomography (PET) camera was applied to 
visualize tumors on the basis of their increased rate of glucose metabolism. In 
xenotransplanted SCID mice co-treated with DOX, UIC2 and CsA the average weight of 
Pgp+ tumors was only ~10 % of the untreated control and in 50 % of the animals we 
could not detect tumors, while DOX treatment alone did not decrease tumor weight. 
These data were confirmed by visualizing the tumors in vivo based on their increased 
18FDG accumulation. UIC2 + DOX treatment also decreased tumor size compared to the 
DOX only treated animals; this result was unexpected, since the UIC2 binding does not 
affect the EC50 value of DOX significantly. In view of the data that UIC2 binding itself 
does not decrease cell viability, but it triggers cell killing by peripheral blood 
mononuclear cells, it seems likely that its in vivo anti-tumor effect is mediated by 
antibody-dependent cell-mediated cytotoxicity (ADCC) besides Pgp inhibition. (The 
manuscript was submitted to PlosOne.) 
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